You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
心脈醫療(688016.SH):前三季度淨利潤預增20.36%
格隆匯 10-23 16:52

格隆匯10月23日丨心脈醫療(688016.SH)公2022年前三季度業績預吿,經財務部門初步測算,預計2022年前三季度實現營業收入為6.64億元,與上年同期相比,將增加15,408.91萬元,同比增加30.20%。2022年第三季度實現營業收入2.05億元,同比增加38.92%。

經財務部門初步測算,預計2022年前三季度實現歸屬於母公司所有者的淨利潤為3.01億元,與上年同期相比,將增加5089.87萬元,同比增加20.36%。2022年第三季度實現歸屬於母公司所有者的淨利潤8584.7萬元,同比增加31.51%。

經財務部門初步測算,預計2022年前三季度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤為2.76億元,與上年同期相比,將增加4250.16萬元,同比增加18.24%。2022年第三季度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤7092.21萬元,同比增加32.96%。

報吿期內,公司銷售收入及淨利潤較2021年前三季度均取得較快增長,繼續保持穩增態勢。創新性產品Castor®分支型主動脈覆膜支架及輸送系統、Minos®腹主動脈覆膜支架及輸送系統、Reewarm®PTX藥物球囊擴張導管等產品進一步提高了公司在主動脈及外周血管介入市場的競爭力,均實現了快速增長,因此公司整體銷售收入較去年同期實現了較快增長,淨利潤同比亦有較大提高。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account